Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Drug adherence low in pregnant women with RA

24 Nov 2019

Women with rheumatoid arthritis (RA) appear to have low utilization of medications safe to take during pregnancy, commonly discontinuing their medications in the first trimester, a recent study has found.

The study used population-based administrative data and included 1,730 singleton pregnancies in 1,301 women with RA (mean age at delivery, 31.4 years). Researchers evaluated the utilization of RA medications, such as conventional synthetic disease modifying antirheumatic drugs (csDMARDs), biologics, glucocorticosteroids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs) during 24 and 12 months prior to conception, each trimester of pregnancy, and 12 months after delivery.

With regard to medication use, the most frequently used csDMARDs throughout the perinatal period were antimalarials (20.8 percent before conception, 7.8 percent during pregnancy and 13.1 percent postpartum) and sulfasalazine (8.4 percent, 2.3 percent and 4.6 percent). Methotrexate was the second most frequently used csDMARD before conception (10.9 percent), but this dropped to <1 percent during pregnancy.

Use of ciclosporin, gold, leflunomide and minocycline prior to conception was also low at 0.6 percent, 2.8 percent, 1.0 percent and 2.4 percent, respectively, with a further decline during pregnancy. Biologics used were predominantly antitumour necrosis factor inhibitors (anti-TNFs; 4.3 percent prior to conception, 1.9 percent during pregnancy and 4.5 percent postpartum). Pattern of use was similar for GCs and NSAIDs.

The rate of medication discontinuation was high in the first trimester of pregnancy, particularly that of antimalarials (57.3 percent), azathioprine (59.1 percent), sulfasalazine (69.5 percent) and biologics (50.8 percent).

Factors associated with discontinuation of antimalarials in the first trimester included maternal age (odds ratio [OR], 0.90, 95 percent confidence interval [CI], 0.86–0.95) and number of rheumatology visits (OR, 0.86, 95 percent CI, 0.75–0.97). On the other hand, biologics discontinuation was associated with prior adverse birth outcome (OR, 0.22, 95 percent CI, 0.05–0.95).

The present data highlight a potential gap in care of pregnant women with RA, according to the researchers. “With growing guidance on the management of pregnancies in RA, it is important to ensure translation of clinical knowledge to women who are making important medication-taking decisions during pregnancy.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.